SARTORIUS STEDIM BIOTECH : revenue, balance sheet and financial ratios

SARTORIUS STEDIM BIOTECH is a French company founded 48 years ago, specialized in the sector Administration d'immeubles et autres biens immobiliers. Based in AUBAGNE (13400), this company of category ETI shows in 2022 a revenue of 2.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SARTORIUS STEDIM BIOTECH (SIREN 314093352)
Indicator 2024 2022 2021 2020 2019 2018 2017
Revenue N/C 2 600 000 € 2 110 000 € 1 877 000 € 2 116 000 € 1 999 000 € 2 198 000 €
Net income 100 200 000 € 154 700 000 € 115 521 000 € 81 227 000 € 56 834 000 € 49 521 000 € 49 463 000 €
EBITDA -6 200 000 € 1 720 000 € -7 652 000 € -3 365 000 € 6 229 000 € -2 187 000 € -2 085 000 €
Net margin N/C 5950.0% 5474.9% 4327.5% 2685.9% 2477.3% 2250.4%

Revenue and income statement

In 2024, SARTORIUS STEDIM BIOTECH generates positive net income of 100.2 M€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 49.5 M€ -> 100.2 M€.

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-6 200 000 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-5 700 000 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

100 200 000 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 21%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 82%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 3.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

20.693%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

82.313%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

2.971

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

26.4%

Solvency indicators evolution
SARTORIUS STEDIM BIOTECH

Sector positioning

Debt ratio
20.69 2024
2021
2022
2024
Q1: 0.0
Med: 9.88
Q3: 66.83
Average +30 pts over 3 years

In 2024, the debt ratio of SARTORIUS STEDIM BIOTECH (20.69) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
82.31% 2024
2021
2022
2024
Q1: 3.14%
Med: 14.37%
Q3: 43.78%
Excellent

In 2024, the financial autonomy of SARTORIUS STEDIM BIOTECH (82.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
2.97 years 2024
2021
2022
2024
Q1: 0.0 years
Med: 0.18 years
Q3: 4.28 years
Average +42 pts over 3 years

In 2024, the repayment capacity of SARTORIUS STEDIM BIOTECH (2.97) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 14862.90. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

14862.903

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-619.355

Liquidity indicators evolution
SARTORIUS STEDIM BIOTECH

Sector positioning

Liquidity ratio
14862.9 2024
2021
2022
2024
Q1: 100.01
Med: 116.58
Q3: 409.86
Excellent +7 pts over 3 years

In 2024, the liquidity ratio of SARTORIUS STEDIM BIOTECH (14862.90) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
-619.36x 2024
2021
2022
2024
Q1: 0.0x
Med: 0.0x
Q3: 7.69x
Watch

In 2024, the interest coverage of SARTORIUS STEDIM BIOTECH (-619.4x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 25 days. Favorable situation: supplier credit is longer than customer credit by 25 days.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

25 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SARTORIUS STEDIM BIOTECH

Positioning of SARTORIUS STEDIM BIOTECH in its sector

Comparison with sector Administration d'immeubles et autres biens immobiliers

Valuation estimate

Based on 277 transactions of similar company sales (all years), the value of SARTORIUS STEDIM BIOTECH is estimated at 223 591 202 € (range 50 248 404€ - 688 416 465€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
277 transactions
50248k€ 223591k€ 688416k€
223 591 202 € Range: 50 248 404€ - 688 416 465€
NAF 5 all-time

Valuation method used

Net Income Multiple
100 200 000 € × 2.2x = 223 591 203 €
Range: 50 248 404€ - 688 416 465€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Administration d'immeubles et autres biens immobiliers)

Compare SARTORIUS STEDIM BIOTECH with other companies in the same sector:

Voir toutes les statistiques du secteur Administration d'immeubles et autres biens immobiliers

Frequently asked questions about SARTORIUS STEDIM BIOTECH

What is the revenue of SARTORIUS STEDIM BIOTECH ?

The revenue of SARTORIUS STEDIM BIOTECH in 2022 is 2.6 M€.

Is SARTORIUS STEDIM BIOTECH profitable?

Yes, SARTORIUS STEDIM BIOTECH generated a net profit of 100.2 M€ in 2024.

Where is the headquarters of SARTORIUS STEDIM BIOTECH ?

The headquarters of SARTORIUS STEDIM BIOTECH is located in AUBAGNE (13400), in the department Bouches-du-Rhone.

Where to find the tax return of SARTORIUS STEDIM BIOTECH ?

The tax return of SARTORIUS STEDIM BIOTECH is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SARTORIUS STEDIM BIOTECH operate?

SARTORIUS STEDIM BIOTECH operates in the sector Administration d'immeubles et autres biens immobiliers (NAF code 68.32A). See the 'Sector positioning' section above to compare the company with its competitors.